David’s interests are in CF respiratory physiology, and he juggles laboratory and scientific clinical-service activity at the WCH with his respiratory and CF research interests. His main focus is on developing a prevention or treatment for CF lung disease using genetic therapies, and he leads the research team based in the Alan Scott CF Research Laboratory at the WCH. More recently he has been collaborating with Perth researchers to develop and test stem-cell therapies for CF in CF mice. He also collaborates with Melbourne, US, UK and Japanese researchers, the latter to use X-ray imaging to measure the effects of treatments in living animal airways. David served on the Respiratory Panel of the American Society of Gene and Cell Therapy for 5 years. His goal is to develop a safe and effective method to prevent or treat the progressing and life-shortening lung disease suffered by CF children.